INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of July 28, 2025 Lead Plaintiff Deadline in the UroGen Pharma Ltd. (URGN) Class Action – Investors With Significant Losses Encouraged to Contact the Firm

Core Points - A shareholder class action lawsuit has been filed against UroGen Pharma Ltd. alleging that the company made materially false and misleading statements regarding its business and operations [1] - The lawsuit claims that the ENVISION clinical study was inadequately designed, lacking a concurrent control arm, which raises concerns about the effectiveness of UGN-102 [1] - It is alleged that UroGen ignored FDA warnings about the study design, leading to a substantial risk that the New Drug Application (NDA) for UGN-102 would not be approved [1] - The lawsuit asserts that the positive statements made by the company regarding its business and prospects were misleading and lacked a reasonable basis [1] Legal Context - Shareholders who purchased UroGen shares between July 27, 2023, and May 15, 2025, and suffered significant losses are encouraged to discuss their legal rights [2] - The deadline for shareholders to request to be appointed as lead plaintiff in the case is July 28, 2025 [3] - Holzer & Holzer, LLC is representing the shareholders and has a history of recovering substantial amounts for investors affected by corporate misconduct [3]